Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02408523 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
A Phase 3 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
NCT02408523 is a Phase 3 study that has completed, run by UCB Biosciences. The registered enrollment target is 242 participants.
The verdict
NCT02408523, a Phase 3 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
Study Summary
Evaluating efficacy \& safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age or greater with idiopathic generalized epilepsy currently taking 1 to 3 antiepileptic drugs. Maximum duration of study drug administration is 28 weeks. Eligible subjects may choose to enter the open-label extension study after completion.
Interventions
- OTHER Placebo Tablet
- DRUG Lacosamide Tablet
- DRUG Lasosamide Oral Solution
- OTHER Placebo Oral Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02408523
The ClinicalTrials.gov registry entry for NCT02408523 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Tablet is the first listed.
NCT02408523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02408523 about?
NCT02408523 is a clinical study titled "A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications". Evaluating efficacy \& safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age or greater with idiopathic generalized epilepsy currently taking 1 to 3 antiepileptic drugs. Maximum duration of study drug...
What is the current status of trial NCT02408523?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2015-04. Estimated completion is 2019-06.
What interventions are being tested in trial NCT02408523?
The interventions under investigation include: Placebo Tablet (OTHER), Lacosamide Tablet (DRUG), Lasosamide Oral Solution (DRUG), Placebo Oral Solution (OTHER).
Who is sponsoring clinical trial NCT02408523?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.